To provide clear scientific evidence whether the two most widely established treatments (SSRI and CBT) for patients with depression but without additional somatic diseases can be applied to high-risk patients with poor metabolic control of insulin-treated diabetes and comorbid depression. Here, INS is linked to diabetes mellitus.